[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sint Maartenskliniek\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100621511","phase-3-the-efficacy-and-safety-of-intramuscular-methylprednisolone-in-patients-with-hand-osteoarthritis-100621511",false,"NCT07371572","The Efficacy and Safety of Intramuscular Methylprednisolone in Patients With Hand OsteoArthritis","The Efficacy and Safety of Intramuscular Methylprednisolone in Patients With Hand OsteoArthritis - the IMHOA Trial","IMHOA","Inclusion Criteria:\n\n* Patients with interphalangeal hand OA (according to the EULAR classification criteria 2023) based on patient report (age, morning stiffness) and radiographs of ≤6 months old (osteophytes, JSN (joint space narrowing) and symptom-structure concordance (present if majority (≥50%) of the symptomatic joints demonstrate radiographic findings)).\n* Age ≥ 16 years\n* Have hand pain \\>40mm on a 100mm visual analogue scale (VAS)\n* Have previously experienced failure of at least one conventional type of pain medication, (self-reported of insufficient effect from topical or oral NSAID, etc. with exclusion of paracetamol)\n\nExclusion Criteria:\n\n* Comorbidity\n\n  * Chronic inflammatory (rheumatic) diseases\n  * Infectious diseases\n  * Known Osteoporosis\n  * Known Diabetes\n  * Previous diagnosis of fibromyalgia\n  * Known myasthenia gravis\n* Previous surgical interventions on the hand (e.g. carpal tunnel syndrome, etc.)\n* Use of other Medication: In order to maximize the generalizability of the study interactions between methylprednisolone and co-medication is only prohibited when the Dutch Medication Surveillance System (Z-index) gives a signal for this interaction.\n* Patients with a contraindication for MP\n\n  * Current Gastric and duodenal ulcers\n  * Current infections\n  * Liver cirrhosis\n  * Pregnant or breastfeeding\n  * Known non-response or intolerance for MP\n* Not able to read or write the Dutch language\n* Neurological diagnosis\n\n  * Epilepsy\n  * Risk of psychiatric disorder","ALL","16 Years",{"count":20,"type":21},212,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this clinical trial is to determine the efficacy and safety of intramuscular methylprednisolone in patients with hand osteoarthritis. The main question it aims to answer is what the difference is in hand pain 4 weeks after the first injection with methylplrednisolone. This main goal will be assessed in the first 16 weeks, the RCT phase. Researchers will compare 120mg methylprednisolone with 40mg methylprednisolone and placebo to see if there is a difference in hand pain after 4 weeks.\n\nParticipants will be asked to visit the hospital for:\n\n* injection of the study material\n* ultrasound assessment\n* physical examination like joint assessments and grip strenght\n* examination of blood\n* x-ray of the hand\n\nIn phase 2, from week 16 to 48, an open label phase focusing on treatment strategy and safety. In this phase all participants may receive intramuscular methylprednisolone on demand at the dosage of 120mg only if they fulfil the following conditions: hand pain \\> 30mm on a VAS (0-100mm) and a minimum of 16 weeks interval between two consecutive injections. Therefore, a maximum of two injections could be received during this period. Irrespective of that, all participants will be followed-up until week 48 when the end-of-study visit will take place.",[27],"Hand Osteoarthritis","RECRUITING","2026-01-19",{"date":31,"type":32},"2026-01-28","ACTUAL",{"date":34,"type":32},"2025-10-28",{"date":36,"type":21},"2028-11",{"name":38,"class":39},"Sint Maartenskliniek","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100605262","phase-4-redo-jak-dose-reduction-of-janus-kinase-inhibitors-in-patients-with-inflammatory-rheumatic-diseases-100605262","NCT07160231","REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases","REDO-JAK: Dose REDuction Of JAnus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases","REDO-JAK","Inclusion Criteria:\n\n* Patients ≥ 16 years of age\n* Clinical diagnosis of RA, PsA or axSpA\n* Treated with a JAKi (monotherapy or combination with csDMARDwith a JAKi dose ≥ 50% of the authorised dose)\n* LDA or remission for at least 6 months according to accepted criteria for the specific disease and\u002For the judgement of the treating rheumatologist and patient. (RA: DAS28-CRP \\\u003C 2.9; PsA: PASDAS ≤3.2 and psoriasis mBSA involvement ≤3%; axSpA: ASDAS \\\u003C2.1.)\n\nExclusion Criteria:\n\n* Comorbidity for which continued JAKi treatment is expected to be necessary (e.g. active Crohn's disease, ulcerative colitis)\n* Life expectancy ≤12 months\n* Pregnancy (JAKi are contra-indicated during pregnancy, therefore we do not expect patients using a JAKi while pregnant)\n* Patients who are enrolled in other trials that might mutually interfere\n* Not able to provide informed consent",{"count":50,"type":21},200,[52],"PHASE4","The goal of this clinical trial is to assess the effectiveness of a disease activity guided dose reduction strategy of Janus kinase inhibitor (JAKi) compared to disease activity guided JAKi continuation in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who are in a state of low disease activity or remission while on JAKi. The main question it aims to answer is:\n\nIs a disease activity guided dose reduction strategy for JAKi not inferior in terms of efficacy compared to disease activity guided JAKi continuation in patients with RA\u002FPsA\u002FaxSpA that are currently in a low disease activity\u002Fremission state?\n\nResearchers will compare a disease activity guided dose reduction strategy for JAKi to disease activity guided JAKi continuation in patients with RA\u002FPsA\u002FaxSpA that are currently in a low disease activity\u002Fremission state to see if a disease activity guided dose reduction strategy for JAKi is not inferior in terms of efficacy compared to disease activity guided JAKi continuation.\n\nParticipants will:\n\n* Follow a JAKi dose reduction strategy or will continue using JAKi in the same dose\n* Study (telemonitoring) visits are planned every 3 months\n* At every visit, patients are asked to complete patient-reported outcomes that assess daily functioning, health-related quality of life, pain, fatigue, productivity loss, medical consumption and medication adherence.",[55,56,57],"Rheumatoid Arthritis (RA)","Psoriatic Arthritis (PsA)","Axial Spondyloarthritis (AxSpA)",[59,60,61],"disease activity guided dose reduction","Janus kinase inhibitors (JAKi)","disease activity guided JAKi continuation","2025-09-16",{"date":64,"type":32},"2025-09-17",{"date":66,"type":32},"2025-09-15",{"date":68,"type":21},"2028-05-01",{"name":38,"class":39},7,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":40},"100560517","phase-3-the-effect-of-colchicine-on-the-incidence-of-knee-or-hip-replacements-100560517","NCT06578182","The Effect of ColcHicine on the Incidence of Knee or Hip Replacements","The Effect of ColcHicine on the Incidence of Knee or Hip Replacements: a Randomized, Double-blind, Multicentre Study in Symptomatic Knee or Hip Osteoarthritis","ECHO","Inclusion Criteria:\n\n* clinical diagnosis of knee or hip OA\n* 45 ≤ age ≤ 80 (upper age limit is similar to that in the LoDoCo2 trial and takes in consideration the lower number of joint replacements in people older than 80 years)\n* documented radiographic changes typical for advanced knee\u002Fhip OA (Kellgren \\& Lawrence score ≥ 2), or at least 2-year history of complaints due to OA in the hip and\u002For knee\n\nExclusion Criteria:\n\n* On a waiting list for primary joint replacement surgery of the hip or knee, irrespective of cause\n* Any absolute contraindication for knee or hip replacement in the future\n* More than one previous hip or knee replacements\n* Other known medical disease that may affect joints\n* Known generalized pain syndromes such as fibromyalgia\n* Renal impairment as evidenced by serum creatinine \\>150µmol\u002Fl or estimated glomerular filtration rate (eGFR) \\\u003C50mL\u002Fmin\u002F1.73m2\n* Liver function impairment as evidenced by serum alanine transferase (ALAT) \\> 3 ULN (upper limit of normal)\n* Blood dyscrasia\n* High frailty (clinical frailty scale ≥ 7) or predicted life expectancy \\\u003C 5 years\n* Peripheral neuritis, myositis or marked myo-sensitivity to statins\n* Current use of colchicine for another indication\n* Intolerance to colchicine\n* use of macrolide antibiotics (i.e. clarithromycin, erythromycin, azithromycin), antimycotics (i.e. ketoconazole, itraconazole and voriconazole), protease inhibitors \\& anti-retroviral drugs (i.e. ritonavir, lopinavir, tipranavir, atazanavir, darunavir, indinavir, saquinavir, and cobicistat), anti-arrhythmic drugs (i.e. verapamil, diltiazem), or immunosuppressant (i.e. cyclosporine)\n* Current enrollment in another trial\n* Incapacitated patients\n* Pregnant or breastfeeding female\n* Fertile female participants not taking sufficient anti-conception\n* Male participants unwilling to use effective contraception during the study to prevent pregnancy","45 Years","80 Years",{"count":82,"type":21},1410,[24],"The goal of this clinical trial is to evaluate the effect of treatment with colchicine 0.5mg once daily as compared to placebo in patients with knee or hip osteoarthritis on the incidence of first occurrence of knee or hip replacement. The main question it aims to answer is:\n\nDoes colchicine lower the number of knee or hip replacements in participants with osteoarthritis?\n\nResearchers will compare colchicine to a placebo (a look-alike substance that contains no drug) to see if colchicine works to treat osteoarthritis.\n\nParticipants will:\n\n* take colchicine every day for 3 tot 4.5 years\n* visit the clinic every year for check-up and tests such as blood samples and x-rays\n* fill in questionnaires every 3 months",[86,87],"Osteoarthritis, Knee","Osteoarthritis, Hip",[89,90,91],"Colchicine","Knee replacement","Hip replacement","2025-02-18",{"date":94,"type":32},"2025-02-20",{"date":96,"type":32},"2025-01-01",{"date":98,"type":21},"2029-03-31",{"name":38,"class":39},""]